A randomized, double-blind, placebo-controlled phase 1 trial of the topical pan–lysyl oxidase inhibitor PXS-6302 in mature scars | Science Translational Medicine
PXS-6302 reduces hydroxyproline and increases microvasculature in mature scars over baseline and placebo treatment, supporting phase 2 studies.
